PSD-95: An Effective Target for Stroke Therapy Using Neuroprotective Peptides
Autor: | Margarita Díaz-Guerra, Lola Ugalde-Triviño |
---|---|
Přispěvatelé: | Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), European Commission |
Rok vydání: | 2021 |
Předmět: |
cell-penetrating peptides
Excitotoxicity Review TP95414 medicine.disease_cause Ischemia NA-1 Protein Interaction Maps Biology (General) nerinetide Stroke Spectroscopy biology Calpain Glutamate receptor General Medicine stroke Neuroprotection Computer Science Applications Chemistry Neuroprotective Agents Excitatory postsynaptic potential neuroprotection Disks Large Homolog 4 Protein excitotoxicity QH301-705.5 ischemia Nerinetide Catalysis Inorganic Chemistry medicine Humans AVLV-144 Physical and Theoretical Chemistry QD1-999 PSD-95 Molecular Biology Ischemic Stroke business.industry Organic Chemistry Neurotoxicity Cell-penetrating peptides medicine.disease nervous system biology.protein business Postsynaptic density Neuroscience |
Zdroj: | Digital.CSIC. Repositorio Institucional del CSIC instname International Journal of Molecular Sciences International Journal of Molecular Sciences, Vol 22, Iss 12585, p 12585 (2021) |
ISSN: | 1422-0067 2019-1057 |
DOI: | 10.3390/ijms222212585 |
Popis: | © 2021 by the authors. Therapies for stroke have remained elusive in the past despite the great relevance of this pathology. However, recent results have provided strong evidence that postsynaptic density protein-95 (PSD-95) can be exploited as an efficient target for stroke neuroprotection by strategies able to counteract excitotoxicity, a major mechanism of neuronal death after ischemic stroke. This scaffold protein is key to the maintenance of a complex framework of protein interactions established at the postsynaptic density (PSD) of excitatory neurons, relevant to neuronal function and survival. Using cell penetrating peptides (CPPs) as therapeutic tools, two different approaches have been devised and advanced to different levels of clinical development. First, nerinetide (Phase 3) and AVLX-144 (Phase 1) were designed to interfere with the coupling of the ternary complex formed by PSD-95 with GluN2B subunits of the N-methyl-D-aspartate type of glutamate receptors (NMDARs) and neuronal nitric oxide synthase (nNOS). These peptides reduced neurotoxicity derived from NMDAR overactivation, decreased infarct volume and improved neurobehavioral results in different models of ischemic stroke. However, an important caveat to this approach was PSD-95 processing by calpain, a pathological mechanism specifically induced by excitotoxicity that results in a profound alteration of survival signaling. Thus, a third peptide (TP95) has been recently developed to interfere with PSD-95 cleavage and reduce neuronal death, which also improves neurological outcome in a preclinical mouse model of permanent ischemia. Here, we review recent advancements in the development and characterization of PSD-95-targeted CPPs and propose the combination of these two approaches to improve treatment of stroke and other excitotoxicity-associated disorders. This research was funded by Agencia Estatal de Investigación (PID2019-105784RB-100/AEI/ 10.13039/501100011033). The cost of publication has been paid in part by FEDER funds. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |